HealthCare Royalty Secures Modeyso Royalty Rights Following Strong Early Commercial Performance
Key Insights
HealthCare Royalty (search) has entered into a royalty monetization agreement for Modeyso (search) (dordaviprone), an FDA-approved treatment for H3 K27M (search)-mutant diffuse midline glioma (search).
Modeyso (search) received accelerated FDA approval in August 2025 for adult and pediatric patients with this rare brain tumor following prior therapy failure.
The drug has demonstrated strong early commercial performance since launch, addressing a significant unmet medical need for patients who previously had no approved treatment options.
HealthCare Royalty (search) (HCRx) has announced a royalty monetization agreement for Modeyso (search) (dordaviprone), marking a significant investment in a breakthrough therapy for a rare and aggressive brain cancer. The agreement involves an undisclosed percentage of royalties from commercial sales of the drug, which has shown strong early performance following its FDA approval.
FDA Approval and Clinical Indication
Modeyso (search) received U.S. FDA accelerated approval in August 2025 for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma (search) harboring an H3 K27M (search) mutation with progressive disease following prior therapy. This approval represents a critical advancement for patients with this rare and devastating form of brain cancer.
Jazz Pharmaceuticals currently commercializes Modeyso (search), bringing the therapy to patients who previously had limited treatment options for this aggressive malignancy.
Strong Commercial Performance
According to Clarke Futch, Chairman and Chief Executive Officer of HealthCare Royalty (search), Modeyso (search) has demonstrated strong early performance since its August launch. "Since its launch in August, Modeyso has demonstrated strong early performance, reflecting the significant unmet need, high awareness driven by advocacy groups, and the value physicians see for patients with H3 K27M (search)-mutant diffuse midline glioma (search)," Futch stated.
The strong commercial uptake reflects several key factors, including the significant unmet medical need in this patient population, heightened awareness driven by advocacy groups, and physician recognition of the drug's value for patients with H3 K27M (search)-mutant diffuse midline glioma (search).
Development History and Strategic Partnership
The royalty agreement involves the Advisory Group representing former Oncoceutics Inc (search). securityholders. Oncoceutics played a crucial role in developing the original molecule ONC201, which eventually became Modeyso (search), taking it from discovery through Phase II efficacy data.
Lee Schalop, co-founder and former CEO of Oncoceutics, expressed satisfaction with the partnership: "On behalf of all of the former shareholders of Oncoceutics, we are pleased that HCRx shares our belief that Modeyso (search) can create significant value as a new treatment option for patients with H3 K27M (search)-mutant diffuse midline glioma (search)."
Addressing Unmet Medical Need
Futch emphasized the therapy's unique position in addressing a critical gap in treatment options. "We believe Modeyso (search) is uniquely positioned to bring meaningful benefit to patients who previously had no approved treatment options, and we are pleased to add this important therapy to HCRx's growing portfolio," he noted.
The investment reflects HealthCare Royalty (search)'s strategy of supporting innovative therapies that address significant unmet medical needs, particularly in rare disease areas where treatment options have been historically limited.